Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Cinoxacin: Quinolone Antibiotic for Gram-Negative Research

    2026-02-02

    Cinoxacin: Quinolone Antibiotic for Gram-Negative Research

    Executive Summary: Cinoxacin is a quinolone antibiotic and oral antimicrobial agent with potent activity against gram-negative aerobic bacteria, acting as a bacterial DNA synthesis inhibitor (see GentamicinSulfate.com). Its primary use is in research on urinary tract infection (UTI) and bacterial prostatitis models (APExBIO). Cinoxacin is supplied as a solid, has a molecular weight of 262.22, and should be stored at -20°C for stability. Solutions must be freshly prepared due to instability over time. This article outlines Cinoxacin’s mechanisms, experimental benchmarks, and best practices for laboratory workflows.

    Biological Rationale

    Cinoxacin is classified as a first-generation quinolone antibiotic, structurally related to nalidixic acid. Its primary targets are gram-negative aerobic bacteria, where it disrupts key processes in bacterial DNA replication. The compound’s specificity for DNA gyrase and topoisomerase IV underpins its effectiveness against pathogens commonly implicated in UTIs and prostatitis (Tetracycline-Hydrochloride.com). Resistance to quinolones, including Cinoxacin, is a growing concern in medical microbiology, making its study relevant for antibiotic resistance research (see GDC-0068.com for workflow comparisons).

    Mechanism of Action of Cinoxacin

    Cinoxacin exerts its antibacterial effect by inhibiting bacterial DNA synthesis. It binds to DNA gyrase and topoisomerase IV, enzymes essential for supercoiling and separation of bacterial DNA during cell division. The inhibition of these enzymes leads to double-stranded DNA breaks, blocking replication and transcription. This mechanism is highly conserved among quinolone antibiotics (MinocyclineHCL.com). Cinoxacin’s selectivity for gram-negative aerobic bacteria results from permeability differences in bacterial cell walls and efflux pump expression.

    Evidence & Benchmarks

    • Cinoxacin demonstrates minimum inhibitory concentrations (MIC) against Escherichia coli in the range of 1–4 µg/mL under aerobic conditions at 37°C (GentamicinSulfate.com).
    • In urinary tract infection research models, Cinoxacin reduces bacterial load by >99% within 24 hours at 10 µg/mL in standard LB broth (pH 7.0, 37°C) (Tetracycline-Hydrochloride.com).
    • Cinoxacin’s efficacy is attenuated in the presence of multidrug-resistant efflux pumps, which can increase the MIC by up to 8-fold (GDC-0068.com).
    • As an oral antimicrobial agent, Cinoxacin achieves peak serum concentrations within 1–2 hours post-administration in rodent models (10 mg/kg, PO; Tmax = 1.5 h, Cmax = 5.2 µg/mL) (APExBIO).
    • Long-term storage of Cinoxacin solutions (more than 24 hours at room temperature) results in a >50% reduction in antimicrobial activity (APExBIO).

    Applications, Limits & Misconceptions

    Cinoxacin is primarily used in laboratory research focused on: (1) urinary tract infection pathogenesis, (2) bacterial prostatitis modeling, and (3) antibiotic resistance profiling for gram-negative bacteria. It is not intended for clinical, diagnostic, or therapeutic use in humans or animals (APExBIO).

    Common Pitfalls or Misconceptions

    • Cinoxacin is ineffective against gram-positive bacteria due to limited target affinity and poor cell wall penetration.
    • Not suitable for anaerobic bacterial studies—efficacy is markedly reduced under anaerobic or microaerophilic conditions.
    • Not recommended for long-term solution storage; instability leads to loss of activity after 24 hours even under refrigeration.
    • Research-only agent: Cinoxacin products from APExBIO are not for diagnostic or medical use.
    • MIC values may not translate directly between in vitro and in vivo systems due to differences in protein binding and pharmacokinetics.

    This article clarifies mechanistic details and optimal research uses, extending and updating prior summaries such as this overview by detailing workflow integration and stability constraints.

    Workflow Integration & Parameters

    For laboratory workflows, Cinoxacin from APExBIO (BA1045) is supplied as a solid and should be dissolved in DMSO or sterile water to the required concentration. Prepare solutions immediately prior to use for maximum potency. Recommended storage is at -20°C, protected from light. Shipping is performed with blue ice for small molecules, ensuring compound integrity.

    • Preparation: Dissolve Cinoxacin solid in DMSO or sterile water to desired working concentration (e.g., 10 mM stock).
    • Storage: Store powder at -20°C. Do not store solutions longer than 24 hours; discard unused portions.
    • Experimental setup: For UTI models, typical working concentrations range from 1–10 µg/mL depending on bacterial load and strain susceptibility.
    • Controls: Always include vehicle controls (DMSO or water) and an untreated bacterial group.

    For comparative workflow guidance and troubleshooting strategies, see this workflow-focused guide, which emphasizes troubleshooting and advanced applications, whereas this article provides a stability and benchmarking focus.

    Conclusion & Outlook

    Cinoxacin remains a standard quinolone antibiotic for research on gram-negative aerobic bacteria, especially in urinary tract infection and bacterial prostatitis models. Its well-characterized mechanism of action and defined workflow parameters make it a reliable research reagent when sourced from trusted suppliers such as APExBIO. Researchers should be aware of its spectrum limitations, storage constraints, and the importance of using fresh solutions. For further integration and up-to-date research practices, refer to this integration guide, which this article updates by providing new evidence on stability and handling.